10-Q: Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics reported a net loss of $4.9 million for the third quarter of 2024, with a focus on advancing its clinical-stage cancer therapies.

Summary

• Lisata Therapeutics, a clinical-stage pharmaceutical company, reported a net loss of $4.9 million for the three months ended September 30, 2024, compared to a net loss of $5.3 million for the same period in 2023.
• The company's operating expenses decreased to $5.3 million in Q3 2024 from $6.0 million in Q3 2023, primarily due to reduced research and development costs.
• Research and development expenses were $2.5 million for Q3 2024, down from $3.4 million in Q3 2023, mainly due to lower clinical research organization expenses.
• General and administrative expenses increased slightly to $2.8 million in Q3 2024 from $2.6 million in Q3 2023, driven by higher consulting expenses.
• For the nine months ended September 30, 2024, the net loss was $15.4 million, compared to $15.5 million for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled approximately $35.9 million as of September 30, 2024.
• Lisata believes its current cash and marketable securities will fund operations for at least the next 12 months.
• The company is advancing its investigational product, certepetide, through multiple Phase 2 clinical studies for various solid tumor types.
• Lisata is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While the company is still operating at a loss, there are positive signs such as reduced operating expenses, promising clinical trial results, and a solid cash position. The company's ability to raise capital and navigate regulatory hurdles remains a risk, but the overall sentiment is cautiously optimistic.

Positives

• The net loss for the third quarter of 2024 was lower than the same period in 2023, indicating improved financial performance.
• Operating expenses decreased in Q3 2024, primarily due to reduced research and development costs.
• The company has a solid cash position of $35.9 million, which is expected to fund operations for at least the next 12 months.
• Lisata is actively advancing its clinical programs with multiple Phase 2 studies underway.

Negatives

• The company continues to operate at a loss, with a net loss of $4.9 million for the third quarter of 2024.
• General and administrative expenses increased slightly in Q3 2024, driven by higher consulting expenses.
• The company's history of operating losses and liquidity challenges may make it difficult to raise capital on acceptable terms.

Risks

• The company's ability to obtain sufficient capital or strategic business arrangements to fund operations and expansion plans is a risk.
• There is a risk that a market may not be established for the company's products or that the company may not capture a meaningful share of the market.
• Scientific, regulatory, and medical developments beyond the company's control could impact results.
• The company's ability to complete planned clinical trials on time is subject to delays associated with patient enrollment and other factors.
• The company's ability to diversify its pipeline of development product candidates is a risk.
• The company's history of operating losses and liquidity challenges may make it difficult to raise capital on acceptable terms or at all.

Future Outlook

Lisata believes that its current cash and marketable securities will enable it to fund current operating expenses for at least the next 12 months. The company will continue to seek additional capital through various means, including potential issuances of debt or equity securities, partnerships, collaborations, and grants.

Management Comments

• The company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience.
• The company's goal is to develop and commercialize products that address important unmet medical needs.

Industry Context

Lisata Therapeutics is operating in the competitive pharmaceutical industry, focusing on developing innovative therapies for solid tumors. The company's approach of using certepetide to enhance drug delivery and modify the tumor microenvironment aligns with current trends in cancer research, which emphasize targeted therapies and immunotherapy. The company's focus on solid tumors, particularly pancreatic cancer, addresses a significant unmet medical need.

Comparison to Industry Standards

• The reported Objective Response Rate (ORR) of 59% in Lisata's certepetide trial for mPDAC is notably higher than the 23% ORR observed in the MPACT trial, which is a benchmark for nab-paclitaxel in combination with gemcitabine.
• The Disease Control Rate (DCR) of over 79% in Lisata's trial also exceeds the 48% DCR in the MPACT trial.
• The median progression-free survival of nearly ten months and median overall survival of over thirteen months observed in Lisata's trial are also significantly better than the less than six months and less than nine months, respectively, in the MPACT trial.
• These results suggest that certepetide may offer a more effective treatment option for mPDAC compared to the current standard of care.
• However, it is important to note that the MPACT trial was a Phase 3 trial, while Lisata's trial was a Phase 1b/2a trial, and direct comparisons should be made with caution.

Legal Proceedings

• In May 2021, Cend received a written threat of litigation from Lingmed Limited.
• In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court.
• On March 25, 2024, the company entered into a settlement agreement with Lingmed, requiring a payment of $0.5 million and future milestone payments.
• On April 9, 2024, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims.

Stakeholder Impact

• Shareholders may be impacted by potential dilution from future equity offerings.
• Employees are impacted by the company's financial performance and the use of equity-based compensation.
• Patients with solid tumors may benefit from the development of new therapies.
• The company's suppliers and creditors are impacted by its financial stability and ability to meet obligations.

Next Steps

• The company will continue to advance its clinical programs for certepetide in various solid tumor types.
• Lisata will continue to seek additional capital through various means.
• The company will continue to explore out-licensing and partnering opportunities for its intellectual property.

Key Dates

Keywords

Certepetide, Clinical Trials, Oncology, Pharmaceutical, Cancer Therapy, Research and Development, Solid Tumors, Financial Results, Biotechnology, Drug Development